Question special
Lead Moderator

The discussion article questions if the concept of an “antibiotic course” is still valid. However, for many infections the ideal duration remains unknown, and observational trials of duration are often fraught with bias. Where is the research headed? Should we continue to define the safety of standardized shorter courses of antibiotics, or should we investigate an individualized approach through symptom scores or biomarkers?